Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Finished Goods (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Finished Goods for 15 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 2.85% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Dec 2025, up 2.85% year-over-year, with the annual reading at $5.4 million for FY2025, 2.85% up from the prior year.
  • Finished Goods for Q4 2025 was $5.4 million at Harvard Bioscience, down from $5.9 million in the prior quarter.
  • The five-year high for Finished Goods was $6.8 million in Q1 2022, with the low at $4.8 million in Q3 2024.
  • Average Finished Goods over 5 years is $5.5 million, with a median of $5.5 million recorded in 2021.
  • The sharpest move saw Finished Goods soared 32.93% in 2022, then dropped 24.33% in 2023.
  • Over 5 years, Finished Goods stood at $5.6 million in 2021, then decreased by 7.49% to $5.2 million in 2022, then dropped by 1.97% to $5.1 million in 2023, then grew by 1.99% to $5.2 million in 2024, then increased by 2.85% to $5.4 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $5.4 million, $5.9 million, and $5.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.